Wednesday, July 8, 2026

Patent intelligence · US

US 12121828

Systems and methods of isolation of gallium-68

granted A61KA61K51/0402A61K51/0497A61K51/083
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 3
Patent details — US 12121828
Jurisdiction
US
Status
granted
Grant date
Oct 22, 2024
Expiration
Oct 17, 2044
Applicant
Telix ARTMS Inc.
Claims
21
CPC classes
A61K, A61K51/0402, A61K51/0497, A61K51/083
View on Google Patents ↗

Quick answer

US 12121828 (Systems and methods of isolation of gallium-68) is held by Telix ARTMS Inc.. Status: granted. Granted Oct 22, 2024. Expires Oct 17, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Telix ARTMS Inc.
Grant date
Expiration
Claims
21
CPC classes
A61K, A61K51/0402, A61K51/0497, A61K51/083, A61K51/088

More from Telix ARTMS Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12383636

    Marking precursor with squaric acid coupling

    Telix Pharmaceuticals Limited · Expires Aug 7, 2045

    granted
  2. US 12329829

    Kit for radiolabelling with 68GA comprising a metal inhibitor

    Telix Innovations S.A. · Expires Jun 12, 2045

    granted

Frequently asked questions

What is US patent 12121828?

US 12121828 (Systems and methods of isolation of gallium-68) is held by Telix ARTMS Inc.. Status: granted. Granted Oct 22, 2024. Expires Oct 17, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12121828?

Telix ARTMS Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.

When does US 12121828 expire?

Our index shows an expiration date of Oct 17, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.